Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Generian Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Generian Achieves First Milestones in Mitobridge Collaboration
Details : Under the terms of the agreement, the companies will jointly conduct research and preclinical development activities to identify novel monovalent small molecules that modulate target proteins through activation, stabilization or degradation as potential ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Generian Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Recipient : Generian Pharmaceuticals
Deal Size : $180.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, the companies will jointly conduct research and preclinical development activities to identify novel monovalent small molecules that modulate target proteins through activation, stabilization or degradation as potential ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 29, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Recipient : Generian Pharmaceuticals
Deal Size : $180.0 million
Deal Type : Collaboration
Lead Product(s) : TLC-065
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney d...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
February 11, 2022
Lead Product(s) : TLC-065
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition